Reddit Posts
ARKK's Misfits - A Bet on the Comeback Kings:
CRSPR, Intellia, Beam, Pacific Biosciences, Illumnia, Editas, Invitae... Will any of these companies be huge in the future?
🚀 $37k YOLO DD on Nutella (NTLA) - The Sweetest Play in the Market 🚀
$CRSP CRISPR Therapeutics pending EMA and FDA Aprovel
Hot Stocks: OKTA, KR rise on earnings news; PLUG drops; NTLA climbs as FDA clears trial
Bought NTLA options with 0 volume only one who has shares at strike price 40
What are your thoughts on ARKG ETF now as a long-term play?
What are the worst / most overvalued stocks on the market?
Searing Criticism on ARK's Genomic Bets in FT. What do you think?
CRISPR DD that's not only lazy, but also manages to stack a few levels of uncertainly, meaning only a fool would give this any credence...
Big Pharma destroying small cap Biotech SGMO
Where’s the volume for gene editing stocks (CRSP, EDIT, NTLA, BEAM, etc.)?
DD on DTIL (gene editing company) I am hoping people can critique
Analysis: Stock Trading by U.S. Senators and Representatives
Analysis: Stock Trading by U.S. Senators and Representatives
$BLUE is going to make me green
CRISPR Short Squeeze Coming in Sep
I built a program that tracks mentions and sentiment of stocks across Reddit and Twitter! This week's most discussed and top growing stocks!
$EDIT - up 25% today since my last post yesterday, still a lot of room to run
Listen up degens, EDIT isn't just a soaring stock - it will help humanity
$DTIL fraction of $NTLA and $VERV but same capabilities
Listen up degens, EDIT isn't just a soaring stock - it will help humanity
$ORTX - Massively undervalued GENE therapy co.
$ORTX - Massively undervalued GENE therapy co.
Looking for advice on understanding exit strategies in regards to biotech companies
Intellia Therapeutics to the moon 🌙. $NTLA
Intellia Therapeutics, Inc. (NASDAQ:NTLA), has commenced an underwritten public offering of $400 million of shares of its common
First in-vivo gene editing therapy announces positive results
have you guys heard of intellia therapeutics? (NTLA) gene editing
$NTLA Intellia Therapeutics (CRISPR technology). Might close out or roll the short position. Let's see if it pops Monday. Advice?
$NTLA and $REGN announce that they have successfully corrected a hereditary disease with an infusion of CRISPR
$NTLA and $REGN announce that they have successfully corrected a hereditary disease with an infusion of CRISPR
NTLA, CRSP, EDIT, BEAM, VERV, ARKG likely to fly on Monday
NTLA, BEAM, CRSP, VERV, EDIT, and ARKG likely to fly on Monday
Let’s get a round of applause for all the people who DON’T buy!
Twist Bioscience (TWST) - great biotech play and also working with Microsoft on the future of data storage. Let me know what you think!
$EDIT - your chance to get the breading on your tendies a bit crispr.
$NTLA - poised for growth at a CRISP pace
Mentions
I'm holding nothing but my NTLA shares (one of my most consistent day trades but dipped under my buy-in so I'll wait it out). I trust very little in this market, with this war, with these politics.
NTLA has had an 11% drop in short interest in the last week and is STILL one of the most shorted biotechs. Remainers have about 7 days to exit and this stock is looking very positioned for a run up over the next 2 months. Massive positive sentiment and still a possible short sweez scenario
NTLA: $13.55 Crispr Bio 90% Institutional ownership 40% short interest FDA Holds removed March 2nd 8 Buy ratings since ranging from $18 to $100 with the average around $25 2 anticipated catalysts with research reports coming in the Summer and Fall Run up is coming with potential short squeez and even without the squeeze this is a solid hold
been trying to tell yall about NTLA
Why are we not jumping in NTLA for a short squeeze deez nutz? Like, light retail attention could blow that shit up
Look up NTLA's recent ratings and price prediction and then look how many shorts are stuck in positions they built before the FDA lifted a hold on their research. The most interesting stock I've come across in a while. Risky but looking pretty fucking good for a long play
What yall thinking about NTLA? Big short interest based on an FDA hold that was lifted on March 2nd but shorts still haven't covered.
She's a major NTLA investor now. Unfortunately so am I.
I admit that NTLA is not pennystock, thank you for stating your interpretation.
NTLA is not a penny stock. But good for you for findings it. This is the April play. Phase 3 data is released in April. The call to put ratio is crazy bullish. Look at the April $20/25$ calls. Intellia is hiring like crazy for commercialization. Currently #2 most shorted stock. It either means the shorts know and have know since the beginning of phase 3 ,after seeing 97% success rate for HALEO that it's going to fail OR they piled in after the patient died in magnitude. Now all the issues have resolved, except the guy is still dead. Phase 3 data is coming out next month, check any AI model, it's an 85% success rate, because I don't know anything about science I trust AI. Either you lose half in April on bad phase 3 data( 20% chance I would say) or %100 gain MINIMUM because of the shorts. Some analysts say it's a $100 stock, it's been there before. I think it's going to 34$ on good news by end of May. Good find. I've tried to post this on wsb but don't have enough karma or whatever
Ah yes NTLA my favorite “penny stock”
Good that you're starting, seriously most people just don't. Honest feedback though, you've got 15 positions across $900. That's a lot of complexity for not much capital yet. Each position is basically a rounding error and the transaction costs plus mental overhead of tracking all this isn't really worth it at this stage. The speculative stuff specifically (JOBY, ACHR, NTLA, EDIT) these are genuine moonshots. Not saying they can't work but at $12-25 each they're not moving your portfolio if they 10x, and they can go to zero. EDIT is already down massively from its highs and the gene editing space has been brutal for smaller players. Three gene editing stocks (CRISPR, NTLA, EDIT) is also a lot of overlap in a sector that's still years from widespread clinical revenue. What I'd actually do in your position: simplify hard. VOO as the core, maybe one or two high conviction individual names you genuinely understand and believe in, and just keep adding the $400/month consistently. At this portfolio size compounding on VOO alone will outperform the complexity of managing 15 positions. The instincts are there, semiconductors, defense, biotech are real themes. But the execution is spread too thin to matter yet. What's the thesis on JOBY and ACHR specifically? Genuine question, just curious what drew you to both.
NTLA did an ATM offering I think it basically caps their price at ~15
Day 2 of the world missing the short squeeze set up perfectly for NTLA….
NTLA, was at 28 and got hammered because of death in clinical trial and fda pause. Death was unrelated to drug and fda resumed trial with minimal changes yesterday. 40% short interest with great data so far in their multiple phase 3 trials
Does nobody care about NTLA? Just got off fda hold, 40% short interest, this used to be the whole point of posting here
Participating in Shorts slaughter on $NTLA around market open
40% short and FDA hold is going to get lifted. NTLA Set those sell orders HIGH
I like investing in biotech, have never invested in EDIT (or CRSP, NTLA are other ARKG-ish names that have often come up.) "biotech winter" There's a lot of things that have done well. XBI actually had a good year last year. " if literally anything goes right (data, partnership, asset sale, etc) the stock could reprice hard." True, but at $2, you have to take into account that a lot EDIT-specific has not gone right, it isn't just the sector. This isn't down 97% since late 2021 because of factors beyond the company.
I like picking up the pieces on oversold biopharma (as long as it has a pretty solid chance and continuing). I made good money on NTLA doing that. In with 9k shares.
NTLA keeps creeping higher and higher then cools off. It used to be at $27 and due to a botched trial, caused it to go down to $9. The botched trial if I remember right wasn't related to what they were trailing but the patient did die so the correlation scared holders.The hault just got lifted. So I'm definitely gonna buy all these pull backs.
Not a penny stock but practically was this fall, I'm so stoked the hold has been lifted on NTLA. I loaded that fall dip and have been holding for a while.
Man I bought NTLA years years ago, while they were in lawsuit with another company over the tech. I sold 20% down and shortly after they won the suit. Man I didn't learn back then how to hold stocks yet.
CRSP and NTLA are have the biggest potential in gene editing.
NTLA. I keep saying it every day.
Anyone taking about NTLA here? Great WSB play. Trading at $26 in fall based on expectations of approval of HAE gene therapy treatment, had a patient die in phase 3 and an FDA hold. Stock dropped to $8. Turns out patient died of unrelated surgical complications. Stock now surging based on expectations of lifting FDA hold. Back up to $13.50 now and very likely headed back to $20s. Also, with the death, there's a 35-40% short float getting...dare I say it...squeezed!
Whelp Cathie is loading up on NTLA... might as well burn my lil calls 😢😢😢
APLD and NTLA for next week... Get some lottos, they're cheap and you don't need the money anyway 🤷🏾♂️
The tracker doesn't show what happened after assignment. I saw that FIG, PRME got assigned away for more premium, but your tracked doesn't show the profit on the shares. I see that you also ran CCs on ACHR, NTLA, but no assignement yet, so still holding them? Are you still holding RCAT? FLY? DNA? Looks like they all may have recovered since assignment, although not sure what price you were assigned at and on what date. Is there away to add columns in the tracker to show the full chain of events after assignment?
Add to that NTLA. One of these days they'll get the pass to keep going. It was one patient out of hundreds who already had significant morbidities being overweight and elderly who caused the trial pause. The stock is so crazily shorted right now. One of these days in the next couple of months it's going to explode.
This is how I feel with NTLA
Surprised no one mentioned CRISPR stocks like CRSP NTLA CRBU
The only reason to care about spot price over market cap is if you are buying a contract that specifies a minimum of 100 units or something (like a call option). Do you have $1000 to invest and want to buy a call? I think NTLA could definitely rebound to the $15-20 price point if its clinical trial that was halted resumes.
TSLA: FSD solved + Cybercab = Big Growth RKLB: Neutron = Big Growth NTLA: Gene editing treatments almost ready for primetime. NTLA got excessively beaten up for one Phase 3 death and a FDA pause. Should bounce back fully in 2026. Possible 2021 highs if data looks really good.
this aged well lol went from 100% to 0% profit on NTLA !
Thoughts on NTLA boys? Easy 2x?
Along with CRBU, have you looked at EDIT and NTLA? One person that ties these all together is Jennifer Doudna. Looking into her was how I found out about CRBU years ago. I agree with their financial responsibility, and they've maintained it over the years. I think this with the relationship to Doudna are important as the companies are serious and aren't at risk of "being stupid" (e.g. out of nowhere turning into a crypto treasury company like Leap Therapeutics). If you are able to share those RE tickers, I would like to know or at least know a good source for them to save me a search. Would appreciate it greatly.
Have to say, I recently lost a ton of money in NTLA. Hoping this one is a grower and I can sell in the green 😅
Not a penny but Intellia Therapeutics (NTLA) is a bargain right now. Stock plunged because a patient with pre-existing conditions died during a Phase 3 trial, pausing it, but there's little to indicate the treatment itself (nex-z) was responsible.
Um... i just loaded up on a bunch of NTLA. Anyone else want to get rich with me?
Cathie Wood also bought NTLA
No it’s not entirely new I agree. What’s new is it working for multiple cancers and the potential for multiple chemo options with the enhancer molecule added in combination which is protected by patent for this specific combination and has protection for other combinations. It’s a platform not just a single drug they are making. I didn’t say it’s the number one reason they don’t work. I said it’s a big reason. Take a look at NTLA and their phase 3 that’s on pause right now because of one patient’s DILI. Phase three has more patients so yes what was true of safety and efficacy in small cohorts in phases 1 and 2 may be invalidated. Probably the number one reason is efficacy doesn’t pan out in 3 as compared to 2 like you said though. Their dilution was at a much better valuation than their last dilution. I’m excited for the phase 2 triple negative breast cancer results. Cheers
Picking up some NTLA calls for earnings. I might be wrong, but looks like the shorts covered on bad news @ around 10 bucks pre-market, and the thing has quieted, i.e. calls are cheap. I'm not a degen gambler though, so do your own research.
Bottom is in on NTLA. I capitulated.
Watch NTLA. It'll rebound. It's expected to bottom out soon with a much higher price target in the next three months.
Holy shit i just noticed how NTLA got absolutely crushed the other day! Absolutely insane dump, I’ve learned my lesson already with bio stocks, but wow thank god I didn’t get greedy and buy into it after I had successfully rode the CRSP pump.
That NTLA v just bought me a new lambo
NTLA isn't just a regular biotech stock. They're at the forefront of a revolutionary technology that will change the world the same way the computer did.
After yesterday's NTLA meltdown, doesn't that have more upside from a rebound?
NTLA made me more than Nvda in the today lmao
I thought NTLA was short for nutella and now I’m broke
Yeah that was a great lesson for me. I bought at $1.12, and saw that 7x and thought it would keep going. Then I held when it dipped, and went back to $4. And I should have sold then, but thought it would go up so I waited. Then I saw $3.50 and thought I’d wait for it to go back to $4. Then it went to 2.90 and I thought I’d wait until it went to $3. And then I finally sold at $2.76. Still made a couple grand, but not what I could have! First time trading, this taught me a lot 😆. Taking emotion and hope out and approaching things moving forward with more calculation and having firm entry and exit positions. Bought ASST this morning at $1.47 and when it stayed at $1.50 for a couple hours I just sold and looked at NTLA’s dip and bought in there at $13.70. That’s back up to $14.70, I’m going to get out of there soon too.
Y'all having a great day while I sit on NTLA.
I'm looking at $NTLA as well. One thing I don't like is that stock recovery isn't 100% post-event. I might trade sideways for a bit before moving back up. Examples below didn't really recover and still well below pre-event. Some concerns chatGPT shared with me: Here are a few recent situations that closely map to the scenario you’re dealing with (lead asset, trial pause, safety event) — with how they played out. • Rocket Pharmaceuticals (RCKT) – gene therapy for Danon disease A patient in their Phase 2 pivotal trial (RP-A501) died following a capillary-leak syndrome and acute systemic infection. → The trial was voluntarily paused and the FDA placed a hold. → Stock plunged \~60% intraday. → Later resumed with lower dose; stock recovered \~20% but stayed below prior levels. Takeaway: Safety event ⇒ big drop; resumption ⇒ partial rebound. • Sarepta Therapeutics (SRPT) – gene therapy for Duchenne muscular dystrophy (DMD) Two patient deaths from acute liver failure triggered a pause in shipments and trials. → Stock dropped >40% on the news. Takeaway: Even approved products face serious valuation risk after safety events. • Novavax (NVAX) – vaccine candidate trial hold A motor-neuropathy case in a Phase 2 trial led to an FDA clinical hold. → Stock dropped \~19%. Takeaway: Safety issue in even lower-risk areas causes sharp market reactions. • Intellia Therapeutics (NTLA) One patient developed Grade 4 liver enzyme elevation → company paused dosing in Phase 3 MAGNITUDE trial of nex-z. → Shares fell \~45% pre-market. Important nuance: single patient (\~450+ dosed), appears reversible but still triggered protocol pause. Watch: causality, regulator feedback, protocol changes, resumption timeline.
Ouch NTLA baggies made today
How is NTLA not at $5 right now? Expected value is 0. Another Cathie masterclass.
Wow NTLA down almost 50% did they find something bad in the Nutella or something
Maybe don't panic sell NTLA. I saw another post where the OP says there are health concerns in their trials, but it only happened to one very old dude who is doing fine now. If that is true, this sounds like market overreaction and it will go back up. I don't know if it is, I'm at work and I can't do my own research, but it does sound like it. If that is actually an overreaction, selling now is unwise. It's important to note that I have no skin in the game, so it's easy for me to say what I am saying. I wish I could actually research this, as, if the previous post is accurate, this seems like a good chance to get some quick returns from the overreaction.
Holding CODX, and riding the recovery wave of NTLA (not a penny stock) for some quick gains.
I did a little of the BYND, lost like a grand, finally came to terms with being a huge dumbass and accepted it. this morning NTLA crashed and I lost like 1500 in gains from that. its joever.
Yeah, it went down because of NTLA
A couple of NTLA trials were paused due to liver damage in a patient. I guess the immediate reaction is that this is a potential risk for any crispr trials. Personally, I've loaded up on a few discount crispr stocks in the last 30 mins as I think it's an overreaction. This stuff happens all the time in clinical trials and patient safety is first priority. This was one of 450 patients enrolled in the trial
Why has NTLA trading been halted? It’s only up 2.54%
NTLA, up 208% in last 6 months, and big catalysts coming EOY, and in the next 2 years.
Anyone else here dumb enough to buy NTLA
I've kept an eye on the sector over the years, mostly just because I think it's interesting. Honestly, a lot of the specifics around the science go right over my head. For that reason, I've always found TWST interesting, but not convinced by their financials to touch them. Covid caused some weird valuation swings for the sector, so I don't put much thought into that and try to just focus on what each company is doing now. I've only got a few shares in CRSP (I'm definitely not into investing a large percentage of my portfolio in risky biotechs). I like that they keep enough cash on hand to not need to take desperate funding deals. I also like that they're one of the few with an approved treatment (CASGEVY). They've at least shown that they can bring these treatments to market. I also like NTLA, but it's been a little while since I've really looked at them.
My techmemes like NTLA and AMPX are getting shit on hard today
Move the fuck on and live your life. Focus in living. Focus on the strategy that is working for you and stick with it. If your strategy works, keep doing it. And for the love of God, just get outside and do something so you don't obsess over it all day. Past fomo experiences of mine, for the record: Sold MU a long time ago, after a 40% gain Sold AMD forever ago, 40% gain. A couple times over. Knew about Intel. Missed it Knew about NVDA. Sat on it. Knew about Tesla, sold after a 50% gain. That was in 2016 or 2017. Knew about Amazon when it's PE was 1000. Didn't touch it. Knew about NTLA also, that one has been on a tear. Right now I'm letting OKLO and PLTR just run and get me profits. In another 3 or 6 months I'll sell off the original amount I invested, but I'll keep holding those and let them run. Also I'm going to keep buying VTI. Every day VTI.
Hoping for another NTLA jump
I see how the OP changed the original post in favor of NTLA after I posted this comment 6 months ago. I am long on NTLA
They are likely waiting to release data from more recent studies that should be positive, verify the safety and science, and move the stock price higher. At that point, we should get an announcement that they will be issuing more stock or issuing convertible bonds, or possibly be acquired. A $90 share price gives NTLA a 10B market cap - completely reasonable for the science and technology. Considering there is still 30% short interest in the stock, any good news from the clinical trials could see massive short covering and an opportunity to sell stock at a higher price.
Crispr-cas9 is the hot thing in biotech right now. It’s used for gene editing and in the future gene editing will be able to solve basically any disease ever. CRBU is co-founded by the woman who co-invented the tech and also co-founded NTLA. She is working with CRBU to develope a crispr hybrid RNA-DNA (chRDNA). This chRDNA will make the existing crispr tech work better be more accurate and have less unintended gene edits which have unintended consequences. ChRDNA will make crispr safer and more effective, it is also a platform that can be patented and then CRBU can license it to all the other biotech crispr companies and make billions. Trial data for their two proof of concept therapies CB-010 and CB-011 will be released by end of year. Stock has moved from 0.66 to 2.60 in anticipation but mcap is still around 300m which means this has upside potential to easily 10-20x if the results are good. I’m betting on the competence of Jennifer Dounda who invented crispr, won a Nobel prize, and cofounded NTLA. Bad results kills the thesis but she has proven to be a good bet and the upside far outward the downside here.
Bought some NTLA this morning, already up 5%. Totally fake ass day.
NTLA chart is looking nice honestly
NTLA, BLNE, DFDV before it split. I had it at like 16. It got somewhere above 100. It split, bought more at 34, it got close to 100 again if I remember right before it declined to where it is now. Would have been pretty set if I held it
“what’s the next biotech to triple like NTLA” maybe the other company founded by the NTLA founder? CRBU leaps cause crispr is the future
I saw the ticker NTLA and thought Nutella had its own stock. Maybe I am retarded
I did. 2 stocks. NTLA, and another one i can't remember. Both tanked like a mofo. These guys are regards for a reason.
NTLA. That ticker is for Nutella correct?
Man I'm so glad I bought CRSP, EDIT, and NTLA a few months ago. CRSP +61.9% EDIT +47.2% NTLA +117.4%
NTLA now up 29% on no news
NTLA launching to outer space
Large insider buys on CRSP and NTLA, upcoming conferences, and expectations of big news
I'm in the same positions. UNH/LULU/NVO and PYPL. My other large position in NTLA since gene-editing is going to blow up in 2026.
Are there any news on NTLA?
Ahem, CRSP, JD, NTLA, and SKYT. To Valhalla.
The fact that no one is talking about NTLA is insane
Gene Editing to the Moon CRSP NTLA BEAM
Finally vindicated with NTLA, but now comes the hard part... when to sell?!?!
I like NTLA as both a short and long term play. Excited about their HAE results in January.
Hope Cathy DCAed her NTLA bet.